Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects
Recruiting
N/A
Interventional Study
Congenital Heart Defects
Neurodevelopmental Disorder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 3 – 11
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 1,206 (estimated)
- Sponsor
- Nantes University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The leading cause of birth defects, Congenital Heart Defects (CHD) affect 12 million people worldwide and 41,000 newborns/year in Europe. It's a major cause of life-long morbidity and mortality, and a crucial public health issue. More than 50% of childs born with critical CHD will develop Neurodevelopmental Disorders (NDs), requiring specific care and impairing quality of life. NDs corresponds to …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Child (aged 3 to 11) with critical MCC operated on for heart surgery during the first three months of life
* Parents and child affiliated with or benefiting from a social security or similar scheme
* Parents' and child's good understanding of the French language
* Free, inform…
Contacts